지씨셀
Financials
Valuation Metrics
지씨셀's Market Cap is ₩2335B. At end of 2025 it was ₩3926B. Ranked #767 of 2,421 in KR market (top 32%), #343 of 1,640 on KOSDAQ (top 21%), #84 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 233.53B KRW | KR#767/2,421 Sec#84/231 |
| Revenue | 162.00B KRW | KR#1,136/2,421 Sec#68/231 |
| Net Income | -246.86B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 303.69B KRW | KR#1,029/2,421 Sec#69/231 |
| Net Assets | 190.38B KRW | KR#979/2,421 Sec#69/231 |
| Employees | 811 | KR#309/2,421 Sec#26/231 |
| Value | ||
| P/B | 1.23x | KR#1,642/2,421 Sec#110/231 |
| P/S | 1.44x | KR#1,615/2,421 Sec#94/231 |
| FCF Yield | 3.39% | KR#958/2,421 Sec#59/231 |
| Profitability | ||
| ROE | -129.67% | KR#2,365/2,421 Sec#222/231 |
| ROA | -81.29% | KR#2,389/2,421 Sec#224/231 |
| Op. Margin | -6.70% | KR#1,914/2,421 Sec#127/231 |
| Revenue Growth | -4.97% | KR#1,766/2,421 Sec#168/231 |
| Financial Health | ||
| Debt Ratio | 59.52% | KR#1,086/2,421 Sec#126/231 |
| Total Debt | 51.61B KRW | KR#996/2,421 Sec#68/231 |
| FCF | 7.92B KRW | KR#780/2,421 Sec#45/231 |
| Cash | 1.46B KRW | KR#2,297/2,421 Sec#218/231 |
| Current Ratio | 0.52x | KR#2,130/2,421 Sec#206/231 |
| Dividend | ||
| Div. Growth | -71.42% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -25.95% | KR#1,428/2,421 Sec#104/231 |
| 1M Return | 9.81% | KR#495/2,421 Sec#33/231 |
| From 52W High | -48.05% | KR#1,295/2,421 Sec#98/231 |
| 1Y MDD | -53.78% | KR#1,159/2,421 Sec#96/231 |
| Trading | ||
| Volume | 138,921 shares | KR#626/2,421 Sec#53/231 |
| Trading Value | 2.09B KRW | KR#550/2,421 Sec#52/231 |
| Foreign Own. | 3.39% | KR#1,180/2,421 Sec#108/231 |
| Per Share | ||
| EPS | -15,624 KRW | KR—/2,421 Sec—/231 |
| BPS | 12,049 KRW | KR#850/2,421 Sec#60/231 |
Company Info
Established in 2011 through the acquisition of a cell therapy business, this company expanded its operations by merging with Green Cross Cell in 2021. It encompasses the entire process of research and development, manufacturing, commercialization, and distribution within the cell and gene therapy field, offering cell therapies, specimen testing services, and bio-logistics. The company focuses on developing next-generation cell therapies such as CAR-NK and CAR-T, and is expanding indications to autoimmune diseases in collaboration with US company Artiva.